[CAS NO. 1393477-72-9] Selinexor (KPT-330)
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1393477-72-9]
Store
Catalog
SLK-S7252
Brand
Selleck
CAS
1393477-72-9
DESCRIPTION [1393477-72-9]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 443.31 |
| Molecular Formula | C17H11F6N7O |
| SMILES | C(F)(F)(F)C=1C=C(C=C(C(F)(F)F)C1)C2=NN(/C=C\C(NNC=3C=NC=CN3)=O)C=N2 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2558 mL | 11.2788 mL | 22.5576 mL |
| 5 mM | 0.4512 mL | 2.2558 mL | 4.5115 mL |
| 10 mM | 0.2256 mL | 1.1279 mL | 2.2558 mL |
| 50 mM | 0.0451 mL | 0.2256 mL | 0.4512 mL |
Description
Selinexor (KPT-330, ATG-010) is an orally bioavailable selective inhibitor. Phase 2.
Targets
| CRM1 [1] (Cell-free assay) |
In vitro
As the clinical candidate analog of KPT-185, KPT-330 exhibits similar effects on the viability of T-ALL cells and elicits rapid apoptotic response. KPT-330 also reduces cell growth in MOLT-4, Jurkat, HBP-ALL, KOPTK-1, SKW-3, and DND-41 cell lines, with IC50 values of 34-203 nM.
In vivo
KPT-330 dramatically suppresses the growth of T-ALL cells (MOLT-4) and AML cells (MV4–11) in vivo, with little toxicity to normal haematopoietic cells. In SCID mice with diffuse human MM bone lesions, KPT-330 inhibits MM-induced bone lysis and prolongs survival. Moreover, KPT-330 directly impairs osteoclastogenesis and bone resorption by blocking RANKL-induced NF-κB and NFATc1, with minimal impact on osteoblasts and BMSCs.
References
Synonyms
2-Propenoic acid, 3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]-, 2-(2-pyrazinyl)hydrazide, (2Z)-
KPT 330
Selinexor
Xpovio
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.